JNJ-101556143
Small molecule
Also known as JNJ-6143, HLD-0915
Evidence outlook · registrational
Prostate Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2028-02-14.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| JNJ-101556143: this drug | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Partial signal | No reviewed efficacy summary in this indication | |
| Talazoparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| 225Ac-PSMA-617 | Phase 3 | Radioligand Therapy (actinium-225) | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Phase 3 | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-87189401 | Phase 3 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Rezvilutamide | Phase 3 | Small molecule | Androgen receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Rinzimetostat | Phase 3 | Small molecule | EED (PRC2) | not yet graded | No reviewed efficacy summary in this indication | |
| Saruparib | Phase 3 | Small molecule | PARP1 inhibitor (next-gen) | not yet graded | No reviewed efficacy summary in this indication | |
| Abiraterone Decanoate | Phase 2 | Small molecule | CYP17 lyase | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-5041 | Phase 2 | Small molecule | Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| MRT-2359 | Phase 2 | Small molecule | GSPT1 | not yet graded | No reviewed efficacy summary in this indication | |
| AMO959 | Phase 1/2 | Small molecule | DNA-PK | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0516 | Phase 1/2 | Antibody–drug conjugate | STEAP2 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0754 | Phase 1/2 | Cell therapy | STEAP2 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD6621 | Phase 1/2 | Multispecific antibody | STEAP2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-1738 | Phase 1/2 | Undisclosed | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Nezastomig | Phase 1/2 | Multispecific antibody | PSMA x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| Olsutamig | Phase 1/2 | Multispecific antibody | PSMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| REGN15505 | Phase 1/2 | Multispecific antibody | PSMA x 4-1BB | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4394 | Phase 1/2 | Antibody–drug conjugate | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| AZD2284 | Phase 1 | Radioconjugate (actinium-225) | STEAP2 | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986460 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| INR731 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| JANX007 | Phase 1 | Multispecific antibody | PSMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-95298177 | Phase 1 | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-98768111 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| VIR-5500 | Phase 1 | Multispecific antibody | PSMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5471713 | —(overall) | Undisclosed | Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| RG6537 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-7525 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow JNJ-101556143 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.